Amgen, Kyowa Kirin Ending Atopic Dermatitis Drug Collaboration
By Colin Kellaher
Amgen and Kyowa Kirin are pulling the plug on a collaboration the drugmakers launched in 2021 aimed at developing a treatment for the inflammatory skin disease atopic dermatitis.
Kyowa Kirin on Friday said the move is due to a strategic portfolio prioritization by Amgen, adding that it will regain control of the global program for the drug candidate, rocatinlimab, including regulatory filings and future commercialization.
Amgen in 2021 made an upfront payment of $400 million to Kyowa Kirin as part of an agreement to jointly develop and commercialize rocatinlimab for atopic dermatitis, with potential in other autoimmune diseases.
Kyowa Kirin, which discovered rocatinlimab, said it remains committed to developing the drug, currently in Phase 3 studies, and that it plans to file for regulatory approval in the U.S. later this year.
Amgen will continue to manufacture rocatinlimab, Kyowa Kirin said.
Thousand Oaks, Calif., biotechnology company Amgen and Japan-based specialty pharmaceutical company have been working together since 1984.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
January 30, 2026 08:54 ET (13:54 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
3 Stocks to Sell and 3 Stocks to Buy for October
The Smartest Moves for Bond Investors Today, and What to Do When You Have Too Many Investments
Undervalued by 15%, This Utilities Stock Could Be an Unexpected AI Winner
The Thrilling 37
United States